Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06732245 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
A Phase 2 study, sponsored by Biomed Industries.
- Not yet
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
NCT06732245 is a Phase 2 study that has not yet begun recruiting, run by Biomed Industries. The registered enrollment target is 224 participants.
The verdict
NCT06732245, a Phase 2 study, has not yet begun recruiting, sponsored by Biomed Industries.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
Study Summary
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
Interventions
- DRUG Tirzepatide
- DRUG NA-931
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2026-08-15 |
| Est. Completion | 2027-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06732245
The ClinicalTrials.gov registry entry for NCT06732245 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biomed Industries, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT06732245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06732245 about?
NCT06732245 is a clinical study titled "Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese". A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
What is the current status of trial NCT06732245?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2026-08-15. Estimated completion is 2027-12-15.
What interventions are being tested in trial NCT06732245?
The interventions under investigation include: Tirzepatide (DRUG), NA-931 (DRUG).
Who is sponsoring clinical trial NCT06732245?
This trial is sponsored by Biomed Industries, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.